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Summary
C2a provides the catalytic center to the convertase
complexes of the classical and lectin-binding path-
ways of complement activation. We determined two
crystal structures of full-length C2a, with and without
a pseudo ligand bound. Both structures reveal a
near-active conformation of the catalytic center of
the serine protease domains, while the vonWillebrand
factor A-type domains display an intermediate activa-
tion state of helix a7 with an open, activated metal-
ion-dependent adhesion site. The open adhesion site
likely serves to enhance the affinity for the ligand
C4b, similar to ‘‘inside-out’’ signaling in integrins. Sur-
prisingly, the N-terminal residues of C2a are buried in
a crevice near helix a7, indicative of a structural switch
between C2 and C2a. Extended loops on the protease
domain possibly envelop the protruding anaphyla-
toxin domain of the substrate C3. Together with a puta-
tive substrate-induced completion of the oxyanion
hole, this may contribute to the high substrate speci-
ficity of the convertases.
Introduction
The complement system plays a crucial role in mamma-
lian immune defense (for review, see, e.g., Walport,
2001a, 2001b). It consists of over 30 fluid-phase and
cell-surface proteins that recognize and kill invading
pathogens, present them to the adaptive immune sys-
tem, and elicit inflammatory responses. Three pathways
activate the complement system: the classical, the lec-
tin, and the alternative pathway. Complement protein
C2 is critical to the classical and lectin pathways be-
cause it provides the proteolytic center to their C3 and
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Center, 3000 DR, Rotterdam, The Netherlands.C5 convertases, which proteolytically activate C3 and
C5, enabling amplification of the complement response,
stimulation of inflammatory responses, opsonization of
pathogenic particles, and initiation of the terminal mem-
brane-attack phase of the complement.
Human C2 (732 amino acid residues, molecular weight
of 100 kDa) is produced as an inactive, heavily glycosy-
lated zymogen consisting of five domains: three N-
terminal complement-control-protein (CCP) domains,
a von Willebrand factor A-type (VWA) domain, and a
C-terminal trypsin-like serine proteinase (SP) domain
(Bentley, 1986) (see Figure 1A). The last two domains,
VWA and SP, form the C2a fragment (residues 224–
732, 70 kDa) that is produced in the proteolytic activa-
tion cascade of the classical and lectin pathways.
Activation starts by binding of the zymogen C2 in a mag-
nesium-dependent manner to activated pathogen-
bound complement component C4b (193 kDa). Proteo-
lysis at Arg-223–Lys-224, by either C1s of the classical
pathway or MASP2 of the lectin pathway, yields a com-
plex of C4b and C2a. This complex is referred to as
C4b2a and is the active C3 convertase of the classical
and lectin pathways. The C3 convertase is instable
and dissociates with a half-life time of 60 s (Kerr, 1980).
Once dissociated, C2a loses proteolytic activity and
cannot reassociate with C4b (Kerr and Parkes, 1984).
C2 and C2a are homologous to factor B and its fragment
Bb of the alternative pathway (39% sequence identity
between full-length proteins as well as protein frag-
ments). Factor B associates with complement compo-
nent C3b and after proteolysis yields the C3 convertase
of the alternative pathway, C3bBb, which has a half-life
time of 90 s (Pangburn and Muller-Eberhard, 1986). The
C3 convertases, C4b2a and C3bBb, cleave C3 into the
anaphylatoxin C3a and C3b. Attachment of C3b to either
C4b2a or C3bBb yields the C5 convertases, C4b2a3b
and C3b2Bb, respectively, that cleave complement
component C5 (reviewed by Rawal and Pangburn,
2001).
C2 and factor B differ from chymotrypsinogens and
trypsinogens in their mechanism of activation. In chy-
motrypsinogens and trypsinogens, cleavage in the N
terminus generates a new N terminus (Ile-16 in trypsin)
that induces formation of the oxyanion hole (Bode,
1979; Khan and James, 1998). In C2 and factor B, in-
stead, proteolysis occurs between the third CCP and
the VWA domain, leaving the VWA domain attached to
the N terminus of the SP domain after activation; thus,
no new N terminus in the SP domain is provided that
may induce oxyanion-hole formation. The VWA domain
is homologous to integrin-inserted (I) domains and con-
tains a metal-ion-dependent adhesion site (MIDAS)
motif. Amino acid residue mutations in the MIDAS motif
abolish hemolytic activity (Horiuchi et al., 1991), indicat-
ing a critical role for the MIDAS motif in convertase for-
mation, stability, or activity. It was hypothesized that
the VWA domain might play an activating role via a con-
formational change similar to that observed in I domains
of integrins in outside-in signaling (Bhattacharya et al.,
2004), where ligand binding at the MIDAS site induces
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(A) Schematic representation of domain topology of C2 and formation of the C3 convertase.
(B) Electron density (2mFo 2 DFc, 4c) of the glycan attached to Asn-447; Asn-447-GlcNac-GlcNac-Man are shown.
(C) Stereo ribbon representation of the C2a-Mn2+ structure; the catalytic triad (blue) in the SP domain (orange), the linker region (light blue) be-
tween the SP and VWA domains (green; its N-terminal residue is indicated by a green sphere), the manganese ion (pink) bound at the MIDAS
motif, and the six glycosylation sites (gray) are shown.
(D) Overlay of C2a (black) and Bb (1rrk, green) (Ponnuraj et al., 2004) superimposed on the SP domains; the different positions of the a7 helix in the
VWA domains are indicated.a w10 A˚ movement of the C-terminal a7 helix (Emsley
et al., 1997, 2000). In analogy to disulphide-bridge engi-
neered I domains, Ponnuraj et al. (2004) made a Bb di-
sulphide mutant (Cys-428–Cys-435) enforcing the VWA
domain in an artificial active conformation in the ab-
sence of ligand C3b. The structure of this engineered
Bb, which was also truncated at the N terminus by 7
residues, showed that the SP domain displays an ac-
tive conformation of the catalytic Asp-His-Ser triad
and a near-active conformation of the oxyanion hole,
i.e., loop 670–674 adopts a conformation similar to
that of mature chymotrypsins and trypsins, except
that peptide bond 671–672 is flipped by w180 (Pon-
nuraj et al., 2004). In this conformation, the negative
charge of the oxyanion intermediate cannot be stabi-
lized. The structure of Bb covalently inhibited by di-iso-propyl phosphate has this peptide plane in the active
orientation, indicating that a fully active site may be
induced by substrate binding (Ponnuraj et al., 2004).
The role of VWA, however, in the molecular mecha-
nisms of convertase formation, stability, or activity re-
mains unclear.
We have expressed human C2 and C2a in mammalian
cells, crystallized C2a, and tested C2 and two C2 glycan-
deletion mutants in hemolytic assays. Here, we present
crystal structures of native, glycosylated C2a, one unli-
ganded and one with a pseudo ligand bound to the
VWA domain. The N-terminal residues, absent in the
truncated Bb fragment (Ponnuraj et al., 2004), play an
important structural role. They interact with the C-termi-
nal tail of VWA and partake in the VWA-SP interface.
Comparison of the SP domains of C2a and Bb indicates
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Placing the C3 structure (Janssen et al., 2005) onto the
SP domains indicates putative interaction sites in the
proteinase-substrate complex.
Results and Discussion
Expression, Purification, and Activity of
Recombinant C2, C2a, and C2 Mutants
Human C2a (residues 224–732) with an N-terminal His6-
tag was stably expressed in baby-hamster kidney (BHK)
cells. Stable BHK-cell lines secreted 10–15 mg C2a per
liter medium. Purification yielded 10 mg C2a per liter me-
dium. Purified C2a runs as a single band on SDS-PAGE
at 70 kDa. The observed molecular weight is in agree-
ment with the extent (10–15 w/w %) of glycosylation ob-
served in human plasma (Tomana et al., 1985). Human
C2 (residues 1–732) and two C2 single-glycan-deletion
mutants (N447D and N451D) and one C2 double-gly-
can-deletion mutant (N447D/N451D) were transiently
expressed in human embryonic kidney (HEK293E) cells.
Native and mutant C2 gave comparable expression
levels of 15–20 mg protein per liter medium. The har-
vested media from BHK and HEK293E cells were tested
for complement activity in a hemolytic assay by using
sensitized sheep erythrocytes. Recombinant C2 in me-
dium showed a hemolytic activity (normalized for con-
centration) that was comparable (98% 6 31%) to native
C2 in normal human serum. No hemolytic activity for the
harvested C2a-containing medium was observed. This
is in agreement with the observation that C2, and not
C2a, associates with C4b to form an active convertase
(Kerr, 1980).
Structure Determinations
Crystals of C2a were obtained by the hanging-drop va-
por-diffusion method. C2a was crystallized with 35%
w/v polyethylene glycol 1000 (PEG-1000) and 0.1 M mal-
onate-imidazol boric acid buffer (MIB-buffer) at pH 7.0.
One crystal was grown in the presence of 20 mM LiCl
and diffracted to a resolution of 2.7 A˚. A second crystal
was grown in the presence of 3% w/v xylitol. We soaked
this crystal in a solution containing 10 mM MnCl2. This
crystal diffracted to a resolution of 2.1 A˚. We refer to
the two diffraction data sets and structures as C2a-Li+
(C2a in the presence of LiCl) and C2a-Mn2+ (C2a soaked
in MnCl2), respectively. Data collection and processing
statistics for both crystals are given in Table 1.
First, we determined the structure of C2a-Li+. For mo-
lecular replacement, we used the structures of the iso-
lated VWA (Protein Data Bank entry 1q0p) and SP
(1dle) domains of factor B as search models (Bhatta-
charya et al., 2004; Jing et al., 2000). The structures of
Bb (Ponnuraj et al., 2004) containing both the VWA and
the SP domain were not made available at that moment.
A clear and correct solution in molecular replacement
was obtained when using the program Phaser (Storoni
et al., 2004). The model was rebuilt by using the graphics
program O (Jones et al., 1991) and was refined by using
programs CNS (Brunger et al., 1998) and REFMAC
(CCP4, 1994; Murshudov et al., 1997). Electron density
allowed modeling of the vector-derived N-terminal Ser;
C2a residues 224–732 (except for residues 395–397,
408–413, and 691–694); partial glycans at Asn-270,Asn-313, Asn-447, Asn-451, and Asn-601; and 38 water
molecules. No additional density was observed at the
putative glycosylation site Asn-631. The final model
had an R factor and an Rfree of 21.2% and 28.7%,
respectively, and displayed good stereochemistry. Sta-
tistics on the model quality are given in Table 1.
Second, we determined the structure of C2a-Mn2+ by
molecular replacement with the structure of C2a-Li+.
The complete model of C2a-Li+ was placed in the unit
cell, and the position of the domains was optimized by
rigid-body refinement with Phaser. Model building and
refinement yielded a final model consisting of the vec-
tor-derived Ser residue; C2a residues 224–732, except
loop 687–693; partial glycans at Asn-313, Asn-447, and
Asn-601; and 133 water molecules. Even though the
C2a-Mn2+ crystal diffracted to higher resolution than
C2a-Li+, less electron density was visible at the glyco-
sylation sites. The final model had an R factor and an
Rfree of 18.9% and 24.0% and good stereochemistry
(see Table 1). An example of electron density is shown
in Figure 1B.
The model of C2a-Mn2+ was used to finalize the mod-
eling of C2a-Li+. In the original C2a-Li+ model, VWA helix
a6 (residues 398–407) was missing. Density at the 0.5s
contour level correlated very well with the superimposed
C2a-Mn2+ structure in this region; therefore, this helix
was included in the model. As a consequence, the R fac-
tor and Rfree dropped from 21.7%/29.1% to 21.2%/
28.7%. Continuous electron density was visible through-
out the a6 helix at 0.8s and for the main chain of residues
401–406 at the 1s contour level. The final position of the
helix in the C2a-Li+ model is very similar to that in C2a-
Mn2+. SP loop 687–694 is most likely disordered in
both crystals. For C2a-Li+ and C2a-Mn2+, 4 and 7 resi-
dues, respectively, of this loop were not modeled. The
Table 1. Crystallographic Data Collection and Refinement
Statistics
C2a-Li+ C2a-Mn2+
Data Collection Statistics
Space group P21 P21
Cell dimensions a = 51.16 A˚ a = 51.48 A˚
b = 75.08 b = 77.19
c = 71.56 c = 70.86
b = 110.32 b = 109.55
Resolution (A˚) 37.5–2.7 50.5–2.1
Completeness (%) 98.5 89.9
Multiplicity 3.6 (3.2) 3.6 (2.9)
Rmerge (%) 8.5 (42) 6.1 (52)
I/sI 13.7 (2.4) 15.1 (1.9)
Refinement Statistics
Number of reflections
(work/test)
13,177/690 26,081/1,389
R/Rfree (%) 21.2/28.7 18.9/24.0
B factor (A˚2) 32.1 22.5
Rmsd bond length (A˚) 0.004 0.003
Rmsd bond angle () 0.674 0.862
Number of protein atoms 3,928 3,994
Number of glycan atoms 144 91
Number of water molecules 38 133
Number of ions — 1 (Mn2+)
Number of ligand atoms — 7 (malonate)
Values in parentheses refer to a high-resolution shell.
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domain orientation, which is possibly due to small differ-
ences in crystallization conditions and soaking of the
C2a-Mn2+ crystal. The separate VWA and SP domains
show root-mean-square coordinate differences of 0.54
and 0.59 A˚, respectively, for all Ca positions.
For C2a-Mn2+, we observed a significant (12s) elec-
tron-density peak at the ion binding position in the MI-
DAS site. We modeled a manganese ion at this position.
The Mn2+ ion displays an octahedral coordination pro-
vided by MIDAS residues Ser-240, Ser-242, and Thr-
317, two water molecules, and one malonate molecule,
originating from the crystallization buffer and acting as
a pseudo ligand. In the case of C2a-Li+, no significant
electron-density peak was present at the ion binding
site, nor was density present for a pseudo ligand. Possi-
bly, the ion-binding site was occupied by the weakly
scattering Li+ ion. However, the resolution (2.7 A˚) of
the diffraction data does not allow for modeling of Li+
binding, and no ion was included at the MIDAS site
for C2a-Li+.
Overall Structure of C2a
The overall structure of C2a is characterized by the VWA
and SP domains that are in close contact (see Figure 1C).
The overall fold of C2a is similar to that of its homolog,
Bb (Ponnuraj et al., 2004), but significant differences
are apparent between the structures. In part, this is ex-
pected given the amino acid sequence identity of 39%
and the differences in glycosylation. C2a has six
whereas Bb has two putative N-linked glycosylation
sites. The orientation of the VWA-SP domains in C2a-
Li+ and C2a-Mn2+ differ by 16.5 and 21.5, respectively,
from the orientation observed in Bb (see Figure 1D). The
VWA-SP orientation differs by only 8 between C2a-Li+
and C2a-Mn2+. In part, these different domain-domain
orientations in C2a and Bb may be due to crystal pack-
ing effects and may reflect flexibility in the domain-do-
main linkage. However, as we will argue below, differ-
ences in glycosylation, the introduced disulphide
bridge in Bb, and, in particular, the N-terminal truncation
in Bb affect the interface region. The absence of muta-
tions and truncations in C2a allows for the analysis of
the unperturbed state of the MIDAS motif, the a7 helix
of VWA, and the VWA-SP interface.
MIDAS Motif
The MIDAS site in C2a is formed by Asp-240, Ser-242,
and Ser-244 from loop bAa1; Thr-317 from loop a3a4;
and Asp-356 from loop bDa5 (Figure 2A). In C2a-Li+,
no ligand is bound and no ion can be observed, whereas
a metal ion and pseudo ligand are clearly bound to the
MIDAS motif in C2a-Mn2+. Putatively, the pseudo ligand,
malonate, originating from the crystallization buffer,
binds in a similar way as the carboxylate moiety of an as-
partate or glutamate residue of the true ligand, C4b. In
C2a-Mn2+, the manganese ion is coordinated by hy-
droxyl groups from residues Ser-242, Ser-244, and
Thr-317 and two waters, one of which mediates con-
tacts with the two MIDAS aspartatic acids 240 and
356. The octahedral coordination is completed by a car-
boxylate oxygen of the pseudo ligand, malonate (Fig-
ure 2A). This conformation of the MIDAS residues is vir-
tually identical to that observed in the engineered Bbstructure and other open and ligand-bound MIDAS
sites (Emsley et al., 1997, 2000; Shimaoka et al., 2003)
(see Figure 2A). Superposition of the MIDAS sites of
C2a-Li+ and C2a-Mn2+ shows that the side chain of
Ser-244 in C2a-Li+ is rotated by w90 and thus points
its hydroxyl away from the metal-binding site and forms
a hydrogen bond with the carboxylate group of Asp-356
(Figure 2A). All other residues in the MIDAS site show
identical conformations in C2a-Li+ and C2a-Mn2+. The
minor rearrangement of Ser-244 may compensate for
the loss of either a +1 or +2 charge when either a Li+
ion or a water molecule, respectively, replaces Mn2+.
In contrast, in an ion-free and unliganded disulphide en-
gineered aL I domain Asp-239 (equivalent to Asp-356 in
C2a) rotates away and hence compensates for the loss
of a +2 charge (Shimaoka et al., 2003). Most surprisingly,
the liganded C2a-Mn2+ and unliganded C2a-Li+ struc-
tures display essentially identical, both open, MIDAS
motifs. Thus, the open conformation of the MIDAS site
in C2a occurs independently of ligand binding.
VWA a7 Helix
In integrin-I domains, ligand binding at the MIDAS site is
coupled to a 10 A˚ displacement of the C-terminal a7 he-
lix from an inactive, closed conformation to one that is
activated and open (Emsley et al., 1997, 2000). Con-
certed movements of loop bAa1 and helix a1 and the
subsequent rearrangement of loops bDa5 and bEa6
transmit the signal from the MIDAS site to loop bFa7
and helix a7. The conformation of these loops and heli-
ces is identical in the unliganded and pseudo liganded
C2a structures. Comparison of C2a with engineered,
open Bb shows that loops bAa1 and bDa5 and helix a1
have similar conformations in the two structures (Fig-
ure 2B). Their conformation corresponds best to the
open conformation of these loops and helix in a I do-
mains (Emsley et al., 2000; Shimaoka et al., 2003) (see
Figure 2B). However, the bFa7 loop and a7 helix differ
between the C2a structures and Bb. The a7 helices differ
by 27–29 in orientation and are shifted approximately
two-thirds of a helical turn toward the MIDAS site in
C2a (Figure 2C). Superposition of C2a with closed and
open a2 and intermediate aL-I domain structures (Shi-
maoka et al., 2003) shows no evident similarities in the
backbone position of loop bFa7 and helix a7. Although
the C2a a7 helix is positioned between the open and
closed states of a2 I domains, it differs from the interme-
diate position observed in the aL I domain due to a tilt of
helix a7 in C2a (Figure 2C).
Based on structural data and molecular dynamic sim-
ulations, Jin et al. (2004) suggest that the position of the
a7 helix in I domains is stabilized by hydrophobic
‘‘ratchet’’ residues that occupy underlying hydrophobic
pockets. For the a2 and aL I domains, respectively, 2
(315-VxxxxxL-321) and 3 (289-LxxFxxL-295) ratchet res-
idues have been identified. Alignment indicates that C2a
and Bb may have 2 hydrophobic ratchet residues, 419-
LxxxxxL-425 in C2a and 430-VxxxxxL-436 in Bb, sug-
gesting that the two VWA domains may occur in an
open and closed conformation similar to those of the
a2 I domain. So far, only an open-like conformation for
Bb has been observed, and the 2 ratchet residues, Val-
430 and Leu-436, are positioned in hydrophobic pockets
according to the activated, open I domains. The
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(A) Left panel: the MIDAS motif of C2a as observed in the structures of C2a-Li+ (gray) and C2a-Mn2+ (green). The MIDAS residues (residue number
and loop names are as indicated), the pseudo ligand malonate, waters (small spheres), and Mn2+ (large sphere) are shown. Middle and right
panels: the MIDAS motif of C2a-Mn2+ and the a2-I domain in an open (1dzi, blue) and closed (1aox, yellow) conformations (Emsley et al.,
1997, 2000).
(B) View of the VWA domain. Left panel: C2a-Mn2+ (green) and engineered open Bb (1rrk, magenta) (Ponnuraj et al., 2004); middle panel: C2a-
Mn2+ (green), closed (1aox, yellow) and open (1dzi, blue) a2 (Emsley et al., 1997, 2000), and intermediate (1mjn, light blue) aL-I (Shimaoka
et al., 2003) domains; and, right panel: coil representation of the strand bF and helix a7, colored as in the middle panel. The conformations of
loops bAa1 and bDa5 and helix a1 transmitting structural changes between the MIDAS motif and helix a7 are indicated.
(C) Position of hydrophobic ‘‘ratchet’’ residues of loop bFa7 and helix a7, colored as in (B). From left to right: C2a-Mn2+ and engineered open Bb,
C2a-Mn2+ and closed a2, C2a-Mn
2+ and open a2, and C2a-Mn
2+ and intermediate aL.situation in C2a, however, differs. The first ratchet resi-
due of C2a, Leu-419, most resembles the situation ob-
served for a2 in the closed conformation and aL in either
the closed or intermediate conformation (Figure 2C). The
second putative ratchet residue of C2a, Leu-425, is lo-
cated at an uncommon position: it sits between the po-
sition that the second a2 ratchet residue occupies in the
closed and open conformation, and it overlaps with the
position of the third aL ratchet residue in the intermedi-
ate conformation (Figure 2C). These differences with
Bb, a2, and aL are possibly due to differences in loop
bEa6 (Figure 2B). This loop is 1 residue longer in C2athan in Bb and adopts a different conformation, with
the side chain of Val-393 occluding the ratchet pocket
(for the second ratchet residue in the open conforma-
tion), as observed in Bb, a2, or aL. In conclusion, C2a
has 2 putative ratchet residues, and their positions cor-
respond best with those of an intermediate conforma-
tion of the a7 helix.
C2a N Terminus
We expected the N terminus of C2a, which is formed
upon proteolysis of C2 in the C4bC2 complex, to be
unstructured. Surprisingly, however, the N-terminal
Structure
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(A) Stereo figure showing the N-terminal residues (ball-and-stick) of C2a positioned in a crevice near the linker (blue) connecting the VWA (green)
and SP (orange) domains. The C2a N terminus is anchored via Ile-225 and Ile-227, which are buried in underlying hydrophobic pockets.
(B) Overlay of C2a-Mn2+ (green) and the closed aL-I domain (1xuo, yellow) in complex with a small-molecule antagonist (Wattanasin et al., 2005).
The binding sites for the N-terminal segment in C2a and the antagonist partially overlap.
(C) Overlay of the N- and C-terminal regions of the VWA domain of C2a (green) and engineered Bb (1rrk, magenta) (Ponnuraj et al., 2004). In C2a,
the N-terminal residues interact with a7, and Ile-225 and Ile-227 occupy hydrophobic pockets. In engineered Bb residues of the C-terminal end of
a7 (Met-443 and Ile-444) occupy these hydrophobic pockets.residues (224–231) are well ordered and positioned in
a groove near the VWA-SP interface region. Strands
bA and bD and the C-terminal end of the VWA domain
form a crevice in which the N-terminal residues are
bound via the side chains of Ile-225 and Ile-227, which
are deeply buried in hydrophobic pockets (Figure 3A).
Furthermore, the main chain of residues 225–227 forms
a small, irregular parallel b sheet with residues 432–434
C-terminal of helix a7. Residues 228–231 form a loop
that connects to the first strand (bA) of the VWA domain.
Additional contacts of the N-terminal residues with the
VWA-SP linker region involve a salt bridge, hydrogen
bonds, and hydrophobic contacts. Thus, the N-terminal
residues of C2a interact extensively with the VWA do-
main and VWA-SP interface.
The observed interactions of the C2a N-terminal seg-
ment with residues in the C-terminal end of the VWA do-
main are absent in the models of the isolated VWA do-
main of factor B (Bhattacharya et al., 2004) and
engineered Bb (Ponnuraj et al., 2004) due to disorder
and truncation of the N-terminal residues, respectively.
The conformation of the N-terminal segment in C2a is,
however, consistent with the observation made by Hin-
shelwood and Perkins (2000). Based on up-field methyl
NMR spectra, these authors suggest that in Bb, and not
in factor B or the isolated VWA domain, the N terminus
235-KIVLD-239 is structurally incorporated in the prox-
imity of an aromatic residue. Indeed, the homologous
residues in C2a (224-KIQIQ-228) are within 4–6 A˚ of 3 ar-
omatic residues (Tyr-389, Phe-429, and Phe-267), which
are identical or homologous aromatic residues in factor
B. Furthermore, the structure of the N-terminally trun-cated Bb shows a similar crevice, which may harbor
the N-terminal residues in full-length Bb. However, bind-
ing of the N terminus in this crevice requires the pres-
ence of the SP domain, because the N-terminal residues
and helix a7 are disordered in the isolated VWA structure
of factor B. The fragments C2a and Bb arise after bind-
ing of C2 and B, respectively, to their cofactors and sub-
sequent proteolysis between the third CCP and the VWA
domain. For proteolysis, the loop with the scissile
bonds, Arg-223–Lys-224 of C2 and Arg-234–Lys-235 of
B, must be exposed. In the structure of C2a, however,
the main-chain atoms of Lys-224 are buried and inac-
cessible to the C1s or MASP-2 proteases. Thus, the
N-terminal residues of C2a and Bb must adopt a confor-
mation in the C4bC2 and C3bB complexes that is dras-
tically different from the conformation observed in C2a.
The binding site for the N-terminal segment in C2a
partially overlaps with the small-molecule antagonist-
binding site observed in the aL I domain (Crump et al.,
2004; Kallen et al., 1999; Wattanasin et al., 2005) (see
Figure 3B). Binding of antagonists locks the aL I domains
in an inactive, closed conformation of both the a7 helix
and the MIDAS site. In contrast, in C2a we observe an in-
termediate-like conformation for helix a7 and an open
conformation of the MIDAS site. This difference is per-
haps correlated with the precise location of binding
the antagonist versus binding the N terminus; i.e., the
antagonists bind adjacent to the helix, whereas the N
terminus binds at the C-terminal end of the helix
(Figure 3B). Comparison of C2a and Bb indicates that
binding of the N-terminal segment likely dislocates the
a7 helix (see Figure 3C). A prominent aspect of binding
Structure of Complement Protein C2a
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Ile-225 and Ile-227 in well-defined hydrophobic pockets.
In engineered, truncated Bb, these two pockets are oc-
cupied by hydrophobic residues Met-443 and Ile-444 of
the C-terminal end of helix a7. Thus, the position of the
a7 helix in Bb is incompatible with binding of the N-ter-
minal segment. We assume that in native, full-length Bb
the N-terminal segment, with Ile-236 and Leu-238, will
dislocate the a7 helix as in C2a (Figure 3C). The structure
of C2a indicates that dislocation of the a7 helix by the N
terminus causes rearrangements in the VWA-SP inter-
face region.
Domain-Domain Interface
The VWA-SP interface area is significantly larger in C2a
than in Bb: 1967 and 1920 A˚2 buried surface area in C2a-
Li+ and C2a-Mn2+, respectively, versus 1320 A˚2 in Bb
(computed by using domain boundaries as defined by
Ponnuraj et al., [2004]). The linker region, residues
433–442, interacts intimately with both the VWA and
SP domains. The contacts between the two domains in-
volve numerous van der Waals interactions, hydrogen
bonds, and three salt bridges. Three aspects contribute
to the difference in buried surface area. First, the do-
main-domain orientations differ by 16–21 in C2a and
Bb and the a7 helices take on different positions. Conse-
quently, the interface has a more compact arrangement
in C2a (Figure 1C). Second, the contribution of the a7 he-
lix to the buried surface area increases from 191 A˚2 in Bb
to 286 and 271 A˚2 in C2a-Li+ and C2a-Mn2+, respectively.
Third, in addition, in C2a, two N-linked glycans at aspar-
agines 447 and 451 are located at or near the VWA-SP
domain interface (Figure 1B; both glycosylation consen-
sus sequences are conserved among the known C2 se-
quences). The glycan at Asn-447 contributes signifi-
cantly (w250 A˚2) to the buried surface area in both C2a
structures. The glycan at Asn-451 contributes another
60 A˚2 in the C2a-Li+ model (this glycan was not modeled
in C2a-Mn2+). Carbohydrate units of the glycan at Asn-
447 make multiple hydrogen bonds with residues of
both the linker and VWA and SP domains. Hydrogen
bonds are formed between the first GlcNAc unit and res-
idues from the VWA a7 helix (Glu-430), the linker (Leu-
433), and the first SP 310 helix (Glu-456) and between
the second GlcNAc unit with the N terminus (Lys-224),
the VWA a7 helix (His-431), and the linker (Asp-434).
To verify the role of these glycans, we made native C2,
two single-glycan-deletion mutants (N447D and
N451D), and one double-glycan-deletion mutant
(N447D/N451D) that were tested for hemolytic activity.
Compared to native C2, the N451D mutant has en-
hanced activity (149% 6 36%), indicating that this gly-
can is not required for activity. In contrast, the N447D
mutant is almost hemolytic inactive (4.0%6 0.1% resid-
ual activity). In the double mutant N447D/N451D, how-
ever, the activity slightly recovers to 22% 6 8%. This
indicates that the N447 interface glycan plays an impor-
tant, but not critical, role in C4b2a convertase stability
or activity.
SP Domain
The catalytic residues, His-487, Asp-541, and Ser-659,
of C2a are in an active conformation. The oxyanion-
hole loop, Lys-656–Ser-659, adopts a conformationsimilar, but not identical, to that of mature trypsins and
chymotrypsins (Figure 4A). As observed in the structure
of Bb (Ponnuraj et al., 2004), one of the oxyanion-hole-
forming peptide planes in C2a (between Lys-656 and
Gly-657) is flipped by w180 compared to trypsin. Al-
though Arg-696 in loop 2 of C2a takes over the role of
Ile-16, which induces oxyanion-hole formation in tryp-
sin, this does not suffice to establish a fully formed oxy-
anion hole. In C2a, the carbonyl oxygen of Lys-656
points inward and makes a hydrogen bond with the cat-
alytic serine hydroxyl, whereas in activated trypsin, the
amide group of Gly-193 points inward to stabilize the
oxyanion-reaction intermediate (Khan and James,
1998). In trypsin, the peptide plane is stabilized in a
proper orientation by a hydrogen bond between Asn-
143 of loop D and the carbonyl of Gln-192 (Figure 4A).
Compared to trypsins and chymotrypsins, C2a and Bb
have a very short loop D and a long loop 2. Nonetheless,
a structural homolog of Asn-143 is not provided in either
C2a or Bb. As suggested (Jing et al., 2000; Ponnuraj
et al., 2004), the ill-formed oxyanion hole may explain
the low proteolytic activity toward peptide substrates
(Kam et al., 1987).
The substrate binding grooves in C2a and Bb differ
significantly from trypsin due to large insertions and de-
letions in surface loops (Figure 4B; with substrate bind-
ing loops labeled according to Perona and Craik, [1997]).
In comparison to trypsin, loops 2, 3, and C are respec-
tively 15, 13, and 9 residues longer, and loops D and E
are respectively 12 and 4 residues shorter in C2a. Nota-
bly, the extended loops 3 and C enclose the left side of
the putative substrate-binding groove (Figure 4B). Thus,
the ordinary S2- and S3-binding pockets appear to be
absent in C2a and Bb. Differences between C2a and Bb
occur primarily in the putative substrate-binding loop
E and loop 2. Loop E is positioned near the interface
region of the VWA and SP domains, and the observed
differences may result from the differences in domain-
domain orientation between C2a and Bb. Loop 2 is 7 res-
idues longer in C2a than in Bb. This loop is disordered in
all structures of C2a and Bb; respectively, 691-KNS-693
and 701-KNQ-703 are missing in all models. These resi-
dues are part of a conserved positively charged stretch
(692–698 in C2a and 701–707 in Bb; these include argi-
nines 696 in C2a and 705 in Bb, which interact with the
oxyanion hole). This stretch may provide a specific elec-
tropositive patch for interactions with substrate C3.
Other surface charges conserved between C2a and Bb
are located within loops A, B, and C near the S1-binding
pocket. As shown in Figure 4B, loops 2 and D on one
side and loops A and B on the other side form a distinct
binding groove, similar to the substrate-binding groove
in trypsin. In contrast, the substrate-binding grooves in
C2a and Bb are delineated by an obstruction formed
by the extended loops 3 and C, which is likely to play
a part in the high substrate specificity of C2a and Bb.
The SP domains in C2a and Bb are in near-active con-
formations. Hence, we may assume that the SP domains
do not undergo large structural changes in cofactor
binding (i.e., in the formation of C4b2a and C3bBb)
and substrate C3 binding. Figure 4C represents a simple
model of the enzyme-substrate complex. This model is
obtained by placing C3 (Janssen et al., 2005) onto C2a,
with the scissile loop oriented in a productive N to C
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(A) Catalytic center and oxyanion hole in C2a-Li+ (left panel) and trypsin (1avw, right panel) (Song and Suh, 1998); the catalytic triad Asp-His-Ser
(light blue), the oxyanion hole (green), and Arg-696 (orange) in C2a, replacing the N-terminal Ile-16 in trypsin, are indicated. In trypsin the main
chain of Asn-143 (yellow) forms a hydrogen bond with the main chain of 192–193. A similar interaction is absent in C2a. Instead, the peptide plane
of 656–657 is flipped and makes a hydrogen bond with the catalytic serine.
(B) Surface representation of the putative substrate-binding grooves; C2a-Li+ (left panel), Bb (1rrk, middle panel) (Ponnuraj et al., 2004), and tryp-
sin (1avw, right panel) (Song and Suh, 1998) are shown. Surface loops 1 (gray), 2 (red), 3 (blue), A (yellow), B (green), C (orange), D (light blue), and
E (pink) are highlighted.
(C) Hypothetical model of C2a placed onto C3 (2a73 [Janssen et al., 2005]); the SP domain of C2a (substrate binding loops are colored as in [B])
and substrate C3 (the flexible scissile loop is indicated by a dotted line) are shown. Domains of C3 are labeled as defined in Janssen et al. [2005].direction in the primary substrate-binding groove. In the
structures of human and bovine C3, the scissile loop is
disordered and exposed to the solvent (Fredslund
et al., 2006; Janssen et al., 2005); in human C3, 9 resi-
dues of the scissile loop (720–728) are absent in the
model, and the Ca atoms of residues 719 and 729 are
11 A˚ apart in the structure of C3. The simple enzyme-substrate model identifies putative interactions between
C2a, or Bb, and C3. Loops 2, 3, and C on the SP domain
likely interact with the anaphylatoxin domain of C3.
These extended loops may increase the contact area
between the two proteins by positioning themselves
around the protruding anaphylatoxin domain. Loops A
and B possibly contact the residues following the
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complementary charges are present, suggesting a sig-
nificant contribution from electrostatic interactions. Pu-
tative interactions of the anchor and MG8 domain of C3
may stabilize the partially disordered loop 2, potentially
aiding in the formation of a mature oxyanion hole. These
latter interactions support a substrate-induced activa-
tion mechanism of the SP domain proposed by Ponnuraj
et al., (2004). Based on the observed VWA-SP orienta-
tion, the VWA domain is located in this enzyme-sub-
strate model close to the C345C domain of C3. It may
thus bridge interactions between the substrate C3 and
the ligand, C4b or C3b, which is thought to bind at the
MIDAS motif on the VWA domain. Of course, given the
size of the molecules, we may expect additional interac-
tion sites that may be important in the substrate affinity
and specificity of the C3 convertases. Modeling these
interactions requires a structure of either C3b or C4b.
Nonetheless, the enzyme-substrate model presented
here identifies a series of potential interaction sites
that will help direct mutagenesis studies.
Concluding Remarks
The two structures of C2a give insights into the possible
roles of the VWA domain in convertase formation and in-
dicate potential primary and secondary interaction sites
between the SP domain and substrate C3. The VWA do-
main of C2a does not require its ligand, C4b, to maintain
an open conformation of the MIDAS motif. The open
MIDAS conformation observed in unliganded C2a-Li+
and pseudo liganded C2a-Mn2+ possibly serves to en-
hance the affinity for C4b. The N-terminal residues of
C2a are buried in the VWA domain, possibly stabilizing
the observed intermediate conformation of the VWA-
a7 helix. The observed structure implies that the N-ter-
minal residues undergo a conformational change from
exposed and accessible to proteases in the C4bC2
complex to inaccessible in C2a. An extensive contact
area is observed between the VWA and SP domains of
C2a. Glycan N447 contributes significantly to the do-
main-domain interface. This glycan is important, but
not critical, for hemolytic activity. As was previously ob-
served in the structure of engineered Bb, the open VWA
domain in C2a does not suffice to induce a fully active
conformation of the SP domain. The proposed sub-
strate-induced activation mechanism, forming a fully ac-
tive oxyanion hole upon C3 binding, possibly involves
loop 2 of the SP domain. In a simple substrate-enzyme
(C3-C2a and C3-Bb) model, the negative charges of
the anchor region and/or MG8 of C3 possibly interact
with the positive charges of the extended, and unique,
loop 2 of C2a and Bb. Extensions of substrate binding
loops 2, 3, and C possibly serve to enhance the contact
area by enveloping the protruding anaphylatoxin do-
main in C3, hence contributing to substrate affinity and
specificity.
Experimental Procedures
Cloning and Expression of Recombinant C2a and C2
The cDNA coding for human C2a was amplified by PCR from
I.M.A.G.E. clone 2191586. Forward primer C2afor (50-GGATCCGCTC
CCTCCTG-30) introduced a BamHI restriction site. Reverse primer
C2rev (50-GCGGCCGCGAGGGGTAAAAAATTCAGGA-30), which an-
neals to the 30 untranslated region, introduced a NotI restrictionsite. The PCR product was cloned in the pCR4-TOPO vector (Invitro-
gen) and sequenced. Next, C2a was ligated as a BamHI-NotI frag-
ment into a pNUT expression vector (Palmiter et al., 1987) that en-
codes the secretion signal peptide of human von Willebrand factor
followed by a hexa-histidine tag. This construct was used for trans-
fection of BHK cells according to the DNA-calcium phosphate
method (Graham and van der Eb, 1973). Colonies were selected
on 100 mM methotrexate. For identification of highly expressing
clones, expression medium was diluted 50- to 100-fold in coating
buffer (50 mM sodium carbonate, 0.02% sodium azide [pH 9.6]),
coated in 96-well plates, and probed with anti-polyhistidine mono-
clonal antibody his-1 (Sigma) followed by horseradish peroxidase-
coupled rabbit-anti-mouse antibodies (DAKO). For large-scale pro-
duction, cells were cultured in a cell factory (Nunc) with Ultroser G
(ITK Diagnostics) as serum replacement. Expression medium was
stored at 220C until further use.
For construction of the human C2 expression vector, a PCR was
performed with forward primer C2for (50-GCAGGATCCGCTCCC
TCCTGCCCT-30) and reverse primer C2rev. The PCR product was
cloned in pCR4-TOPO and sequenced. This plasmid served as
a template for the generation of glycosylation mutants C2-N447D
and C2-N451D and the double glycosylation mutant C2-N447D/
N451D. Mutagenesis was achieved by an ‘‘in house’’ variation of
the QuikChange method. In the case of mutant C2-N447D, a PCR
was performed with limiting amounts (6 pmol) of forward mutagen-
esis primer N447D (50-GGGGTGGGGGACATGTCAGC-30) and primer
C2rev with 100 ng (w25 fmol) pCR4-C2 template and 1.7 U Pfu Turbo
DNA polymerase (Stratagene). After a few PCR cycles, both primers
are exhausted. The PCR product then provides two complementary
mega-primers that, in a QuikChange-like reaction, generate full-
length mutated copies of the template vector. After completion of
the reaction, template vector was destroyed by incubation with
DpnI restriction enzyme (NewEngland Biolabs) for 2 hr at 37C,
and 5 ml of the reaction product was transformed into Top10 cells.
For the construction of mutant C2-N451D, a similar PCR reaction
was performed with primer C2for and reverse mutagenesis primer
N451Drev (50-CAGAGGCGTCTGCTGACATG-30). The double mutant
was constructed by using mutation primers N447Dfor and
N451Drev. Introduction of the respective mutations was confirmed
by sequencing. C2 and C2 mutants were ligated in a modified
pTT3 expression vector (Durocher et al., 2002) encoding a cystatin
secretion signal peptide (Barash et al., 2002) followed by a hexa-his-
tidine tag. Suspensions growing HEK293-EBNA-1 (Epstein-Barr vi-
rus nuclear antigen 1) cells were transfected with polyethyleneimine
(Durocher et al., 2002), and recombinant mutant C2 was transiently
expressed at low serum concentration (w0.1% fetal calf serum).
Expression medium containing C2 was harvested 96 hr after trans-
fection and stored at 220C until further use.
Hemolytic Assay
Hemolytic activity of recombinant C2 was assessed by a C2-depen-
dent hemolytic assay, by using C2-deficient guinea pig serum as
a complement source. The method was similar to that previously de-
scribed for a C1q-dependent hemolytic assay (Roos et al., 2001). In
brief, 1.107 antibody-coated sheep erythrocytes were incubated
with 100-fold diluted C2-deficient serum in the presence or absence
of culture supernatant containing human recombinant C2 or C2a,
normal human serum, or mock culture supernatant, in various dilu-
tions, for 1 hr at 37C. The assay was performed with dextrose gel-
atin Veronal buffer2+ (DGVB2+) as a buffer in a final volume of 200 ml.
DGVB2+ consists of 0.05% gelatin, 167 mM glucose, 0.15 mM CaCl2,
0.5 mM MgCl2 in veronal-buffered saline (1.8 mM Na-5,5-diethylbar-
bital, 0.2 mM 5,5-diethylbarbituric acid, 145 mM NaCl). After addition
of 1.5 ml phosphate-buffered saline and centrifugation, hemolysis
was assessed by measuring OD at 414 nm. C2 hemolytic activity
was calculated as a z value, as described (Roos et al., 2001), fol-
lowed by calculation of hemolytic activity per milliliter and normali-
zation for the concentration of C2 as determined by specific ELISA.
The relative hemolytic activity of mutant C2 was calculated as a
percentage of hemolytic activity of wild-type C2.
Purification of C2a
C2a expression medium was concentrated 10-fold by using a Quick-
stand bench top concentrator (GE Health Care) with a 10 kDa
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8.0. Next, C2a was purified from concentrated medium by using a Hi-
Trap-chelating HP column (Amersham) charged with Ni2+. After
loading, the column was extensively washed with buffer containing
20 mM Tris, 300 mM NaCl (pH 8). Nonspecifically bound proteins
were eluted with 15 mM imidazole in the same buffer. Next, C2a
was eluted at an imidazole concentration of 100 mM. Peak fractions
were analyzed by SDS-PAGE and Western blotting with antibodies
directed against the His-tag. The N-terminal sequence was analyzed
on an automated protein sequencer from Perkin Elmer Applied Bio-
systems 476A, confirming the presence of the expected amino acids
HHHHHHGSKI.
Crystallization and Diffraction Data Collection
For crystallization, purified C2a was dialyzed against a solution con-
taining 20 mM Tris, 50 mM NaCl (pH 7.5) and was concentrated to 15
mg/ml. Crystallization experiments were performed at 20C by using
the hanging-drop vapor-diffusion method and a 1:1 ratio of protein
and reservoir solution. Initial crystals of poor quality were obtained
with reservoir solution consisting of 35% w/v PEG 1000 and 0.1 M
malonate-imidazole boric acid buffer, made by mixing 0.1 M sodium
malonate, 0.1 M imidazol, and 0.1 M boric acid in a 2:3:3 ratio, at pH
7.0. A subsequent screen for additives identified two conditions that
produced crystals suitable for data collection. In the presence of 20
mM LiCl, triangular crystals with dimensions of 0.08 3 0.06 3 0.02
mm appeared after 4–5 days. We refer to these crystals as C2a-
Li+. For data collection, a C2a-Li+ crystal was passed through a 2
ml drop of reservoir solution and rapidly frozen by immersion in liquid
nitrogen. In the presence of xylitol at a concentration of 3%, w/v
crystals of 0.13 0.13 0.1 mm appeared after 5 months. These crys-
tals were soaked for 24 hr in a 2 ml drop of reservoir solution contain-
ing 20 mM NaCl and 10 mM MnCl2 and were then flash cooled in
liquid nitrogen. We refer to these crystals as C2a-Mn2+. Diffraction
data up to a resolution of 2.7 A˚ for C2a-Li+ and 2.1 A˚ for C2a-Mn2+
were collected at ESRF beam-lines ID14-EH2 and ID14-EH4 in Gre-
noble, France. The data were indexed and integrated with MOSFLM
(Leslie, 2006) and were scaled with SCALA (CCP4, 1994). Data statis-
tics are given in Table 1.
Structure Determination and Refinement
The structure of C2a was determined by molecular replacement with
Phaser (Storoni et al., 2004). As search models, we used the coordi-
nates of Protein Data Bank entries 1DLE (Jing et al., 2000) and 1Q0P
(Bhattacharya et al., 2004), representing the SP and VWA domains,
respectively, of factor B. Sequence identities between C2 and factor
B are 39% for these domains. Phaser yielded a clear answer, where
attempts with other programs had failed, placing first the SP domain
and subsequently the VWA domain. Reversing the order, i.e., start-
ing with the smaller VWA domain, yielded the same solution.
The model of C2a-Li+ was iteratively built by using the program O
(Jones et al., 1991) and was refined to near completion with CNS
(Brunger et al., 1998) and REFMAC (Winn et al., 2001). Subsequently,
higher-resolution diffraction data of C2a soaked with MnCl2 were
obtained, and its structure was solved and refined, yielding a more
complete model. The C2a-Mn2+ model was then used to finalize
the model of C2a-Li+. The final R and Rfree factors were 0.21/0.29
for all data out to 2.7 A˚ resolution for C2a-Li+ and 0.19/0.24 for all
data to 2.1 A˚ resolution for C2a-Mn2+. Both models display good ge-
ometry (see Table 1). The final model for C2a-Li+ consists of 497 pro-
tein residues, 11 glycan units, and 38 water molecules. Due to poor
electron density, residues 395–397, residues 408–413, and residues
691–694 were excluded from the model. The final model for C2a-
Mn2+ consists of 502 protein residues, 7 glycan units, 133 water mol-
ecules, and 1 Mn2+ ion. Residues 687–693 are missing due to unclear
electron density.
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